{
  "cik": 1907108,
  "cik_padded": "0001907108",
  "entityName": "Lexeo Therapeutics, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-132085",
      "filed": "2026-03-30",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 397000.0,
        "cash": 63000000.0,
        "eps_diluted": -1.86,
        "free_cash_flow": -98958000.0,
        "net_income": -99961000.0,
        "operating_cash_flow": -98561000.0,
        "operating_income": -109257000.0,
        "stockholders_equity": 246669000.0,
        "total_assets": 268688000.0,
        "total_liabilities": 22019000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.0892653718140504,
        "roa_avg2y": -0.4810095517647908,
        "roa_period_end": -0.37203373429405107,
        "roe_avg2y": -0.5499751039170754,
        "roe_period_end": -0.4052434639131792
      }
    },
    {
      "accn": "0001193125-26-132085",
      "filed": "2026-03-30",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 481000.0,
        "cash": 35014000.0,
        "eps_diluted": -3.09,
        "free_cash_flow": -81632000.0,
        "net_income": -98333000.0,
        "operating_cash_flow": -81151000.0,
        "operating_income": -105766000.0,
        "stockholders_equity": 116842000.0,
        "total_assets": 146942000.0,
        "total_liabilities": 30100000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.2576128446962565,
        "roa_avg2y": -0.6858472043494485,
        "roa_period_end": -0.6691960093097957,
        "roe_avg2y": -0.8536702882666238,
        "roe_period_end": -0.8415894969274746
      }
    },
    {
      "accn": "0001193125-26-132085",
      "filed": "2026-03-30",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 115000.0,
        "cash": 121466000.0,
        "eps_diluted": -12.4,
        "free_cash_flow": -59611000.0,
        "net_income": -66394000.0,
        "operating_cash_flow": -59496000.0,
        "operating_income": -68513000.0,
        "stockholders_equity": 113535000.0,
        "total_assets": 139807000.0,
        "total_liabilities": 26272000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.2314000088078566,
        "roa_avg2y": -0.5605636537868905,
        "roa_period_end": -0.4748975373193044,
        "roe_avg2y": -228.55077452667814,
        "roe_period_end": -0.5847888316378209
      }
    },
    {
      "accn": "0000950170-25-043486",
      "filed": "2025-03-24",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 672000.0,
        "cash": 77335000.0,
        "eps_diluted": -36.36,
        "free_cash_flow": -55232000.0,
        "net_income": -59277000.0,
        "operating_cash_flow": -54560000.0,
        "operating_income": -60509000.0,
        "stockholders_equity": -112954000.0,
        "total_assets": 97076000.0,
        "total_liabilities": 24997000.0
      },
      "period_end": "2022-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.6106246652107628,
        "roe_avg2y": 0.7033508151593536
      }
    },
    {
      "accn": "0000950170-24-028941",
      "filed": "2024-03-11",
      "fiscal_year": 2021,
      "form": "10-K",
      "fundamental_units": {
        "cash": "USD",
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "cash": 135860000.0,
        "stockholders_equity": -55602000.0
      },
      "period_end": "2021-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-132085",
    "filed": "2026-03-30",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2836",
  "sic_description": "Biological Products, (No Diagnostic Substances)",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001907108.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001907108.json"
  },
  "ticker": "LXEO"
}